ArticleScientific reports2013
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Cross-species therapeutics in Plasmodium and Babesia: erythrocyte invasion and conserved drug targets.Tropical animal health and production · 2026Review
- Beyond the mouse: organoids, spheroids, and organs-on-chips as the (inevitable) future of malaria research?Malaria journal · 2026Review
- Immunity beyond borders: non-lethalFrontiers in immunology · 2026Article
- Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.Frontiers in immunology · 2026Review
- The Use of Medicinal Plant-Derived Metallic Nanoparticles in Theranostics.Pharmaceutics · 2022Review
- Potent Virustatic Polymer-Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo.ACS central science · 2022Article
- Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 ofBiomedicines · 2022Article
- A newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies.The Journal of experimental medicine · 2021Article
- Melittin as a promising anti-protozoan peptide: current knowledge and future prospects.AMB Express · 2021Review
- Protective Immunity in Mice Immunized WithFrontiers in immunology · 2020Article
- Killer yeasts exert anti-plasmodial activities against the malaria parasite Plasmodium berghei in the vector mosquito Anopheles stephensi and in mice.Parasites & vectors · 2019Article
- Infection-Induced Resistance to Experimental Cerebral Malaria Is Dependent Upon Secreted Antibody-Mediated Inhibition of Pathogenic CD8Frontiers in immunology · 2019Article
- Humanized Mice as Unique Tools for Human-Specific Studies.Archivum immunologiae et therapiae experimentalis · 2018Review
- Role of Activins in Hepcidin Regulation during Malaria.Infection and immunity · 2017Article
- Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria.Scientific reports · 2017Article
- An ultrasensitive NanoLuc-based luminescence system for monitoring Plasmodium berghei throughout its life cycle.Malaria journal · 2016Article
- Malaria modeling: In vitro stem cells vs in vivo models.World journal of stem cells · 2016Review
- A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Cell host & microbe · 2015Article
- Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei.PloS one · 2015Article
- Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.Frontiers in immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 4 countries.
Funding
Abstract
Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure to protect against P. berghei, despite successful antibody induction against leading merozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Δsmac P. berghei parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.